Dr. Steven J. Chmura is an Associate Professor in the Department of Radiation and Cellular Oncology and Director of Clinical and Translational Research at The University of Chicago.
Steven J. Chmura MD, PhD is the director of Clinical and Translational Research for Radiation Oncology at the University of Chicago for over a decade. He has been actively involved in both the clinical implementation of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) and related translational and clinical research, as well as the integration of SRS and SBRT into other systemic therapies. His clinical interests include breast cancer, limited metastatic disease, immunotherapy, and technologic improvements in the delivery of radiotherapy. Dr. Chmura is a leader in the NCI cooperative groups. His work has led to the first international oligmetastatic trials through NRG Oncology examining the safety of treating lung and breast cancer patients as a Phase II/III trial examining potential improvements to progression-free survival and overall survival. Dr. Chmura's work in radio-immunology has also translated into multiple investigator-sponsored trials along with the now accruing NCI-sponsored (A091605) trial randomizing the role of SBRT combined with pembrolizumab in advanced Merkel cell carcinoma; such integration of ablative radiotherapy and immunotherapy along with advancing the search for biomarkers is currently Dr. Chmura's focus.
University of Chicago
Chicago
- Radiation Oncology Board Certification
2005
University of Chicago
Chicago
PhD - Pathology
1999
University of Chicago
Chicago
MD - Medicine
1999
University of Illinois
Urbana
BS - Biology and Psychology
1992
Correction: Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation.
Correction: Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2025 Oct 06; 222(10).
PMID: 40970935
Erratum: De Novo Oligometastatic Breast Cancer.
Erratum: De Novo Oligometastatic Breast Cancer. J Clin Oncol. 2025 Aug 20; 43(24):2758.
PMID: 40690726
Clinical Parameters Associated With Intracranial Progression Burden Following an Initial Stereotactic Radiosurgery Course in a Multi-institutional Brain Metastases Cohort.
Clinical Parameters Associated With Intracranial Progression Burden Following an Initial Stereotactic Radiosurgery Course in a Multi-institutional Brain Metastases Cohort. Adv Radiat Oncol. 2025 Sep; 10(9):101859.
PMID: 40800218
Radiation-induced amphiregulin drives tumour metastasis.
Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025 Jul; 643(8072):810-819.
PMID: 40369065
Multi-institutional Outcomes after Stereotactic Radiosurgery for Gastrointestinal Brain Metastases.
Multi-institutional Outcomes after Stereotactic Radiosurgery for Gastrointestinal Brain Metastases. Adv Radiat Oncol. 2025 Jul; 10(7):101795.
PMID: 40538502
YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production.
YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. J Clin Invest. 2024 Dec 02; 134(23).
PMID: 39325547
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer.
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
PMID: 39242330
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials.
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
PMID: 39106643
Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites.
Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites. Clin Cancer Res. 2024 May 01; 30(9):1945-1958.
PMID: 38427437
Determinants of Symptomatic Intracranial Progression After an Initial Stereotactic Radiosurgery Course.
Determinants of Symptomatic Intracranial Progression After an Initial Stereotactic Radiosurgery Course. Adv Radiat Oncol. 2024 Jun; 9(6):101475.
PMID: 38690297